Search Result

Results for "

neuron injury

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (6) Akt (9) AMPK (6) Amyloid-β (1) Apoptosis (21) ASK1 (2) Autophagy (6) Bcl-2 Family (2) Calcium Channel (7) CaMK (1) Caspase (1) COX (1) DAGL (1) DNA/RNA Synthesis (2) Dopamine Receptor (3) Drug Derivative (3) Drug Isomer (1) Dynamin (2) Enolase (1) Environmental Pollutants (1) ERK (3) FGFR (1) Fluorescent Dye (1) GSK-3 (1) Heme Oxygenase (HO) (1) Histamine Receptor (1) iGluR (5) Insecticide (2) Isotope-Labeled Compounds (2) JNK (3) Keap1-Nrf2 (5) Lipoxygenase (1) LRRK2 (2) Mas-related G-protein-coupled Receptor (MRGPR) (1) Mitophagy (6) Monoamine Oxidase (3) mTOR (6) Necroptosis (2) Neprilysin (1) NF-κB (6) NO Synthase (3) Opioid Receptor (2) p38 MAPK (4) Phosphatase (1) Phosphorylase (2) PKC (4) Potassium Channel (3) RAR/RXR (1) Reactive Oxygen Species (ROS) (5) Reference Standards (10) SARS-CoV (1) Serotonin Transporter (1) Sigma Receptor (3) Sirtuin (1) Sodium Channel (1) TNF Receptor (2) TNK1 (2) Transferrin Receptor (1) Trk Receptor (3) TRP Channel (2) α-synuclein (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (23) Infection (4) Inflammation/Immunology (14) Metabolic Disease (11) Neurological Disease (61)

By Targets:

5-HT Receptor (6)

Akt (9)

AMPK (6)

Amyloid-β (1)

Apoptosis (21)

ASK1 (2)

Autophagy (6)

Bcl-2 Family (2)

Calcium Channel (7)

CaMK (1)

Caspase (1)

COX (1)

DAGL (1)

DNA/RNA Synthesis (2)

Dopamine Receptor (3)

Drug Derivative (3)

Drug Isomer (1)

Dynamin (2)

Enolase (1)

Environmental Pollutants (1)

ERK (3)

FGFR (1)

Fluorescent Dye (1)

GSK-3 (1)

Heme Oxygenase (HO) (1)

Histamine Receptor (1)

iGluR (5)

Insecticide (2)

Isotope-Labeled Compounds (2)

JNK (3)

Keap1-Nrf2 (5)

Lipoxygenase (1)

LRRK2 (2)

Mas-related G-protein-coupled Receptor (MRGPR) (1)

Mitophagy (6)

Monoamine Oxidase (3)

mTOR (6)

Necroptosis (2)

Neprilysin (1)

NF-κB (6)

NO Synthase (3)

Opioid Receptor (2)

p38 MAPK (4)

Phosphatase (1)

Phosphorylase (2)

PKC (4)

Potassium Channel (3)

RAR/RXR (1)

Reactive Oxygen Species (ROS) (5)

Reference Standards (10)

SARS-CoV (1)

Serotonin Transporter (1)

Sigma Receptor (3)

Sirtuin (1)

Sodium Channel (1)

TNF Receptor (2)

TNK1 (2)

Transferrin Receptor (1)

Trk Receptor (3)

TRP Channel (2)

α-synuclein (1)

By Research Areas:

Cancer (8)

Cardiovascular Disease (23)

Infection (4)

Inflammation/Immunology (14)

Metabolic Disease (11)

Neurological Disease (61)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0627

Metformin Maximum Cited Publications 196 Publications Verification 1,1-Dimethylbiguanide	AMPK Autophagy Mitophagy Apoptosis mTOR	Cardiovascular Disease Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .

HY-17471A

Metformin hydrochloride Maximum Cited Publications 196 Publications Verification 1,1-Dimethylbiguanide hydrochloride	AMPK Autophagy Mitophagy Apoptosis mTOR	Cardiovascular Disease Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .

HY-153169

6PPD-Q 5+ Cited Publications 6PPD-Quinone	α-synuclein Environmental Pollutants	Others
6PPD-Q (6PPD-Quinone) is an environmental pollutant that can be detected in human urine and is widely present in the environment. 6PPD-Q targets and binds to CNR2, CNR1, AA2AR, LCAT, and TRPA1, with CNR2 exhibiting the highest binding affinity, potentially acting as a CNR2 receptor agonist to activate cannabinoid receptors. 6PPD-Q induces intestinal inflammation and barrier damage by disrupting mitochondrial function, reducing neuronal glycolysis metabolites and TCA cycle intermediates, and exacerbating α-synuclein (α-syn) aggregation. 6PPD-Q is applicable in research on environmental toxicology, neurodegenerative diseases, and inflammation-related disorders .

HY-W013375

Thiorphan 3 Publications Verification	Neprilysin	Neurological Disease
Thiorphan is a selective neprilysin (NEP) inhibitor with an IC₅₀ of 6.9 nM. Thiorphan competitively binds to NEP and blocks its activity, preventing the degradation of neuropeptides such as substance P (SP) and neurokinin NKA. In the field of neonatal brain injury research, Thiorphan can increase the levels of SP and NKA, activate NK1 and NK2 receptors and downstream transduction pathways, and inhibit excessive activation of NMDA receptors. Thus, Thiorphan can protect neocortical neurons from excitotoxic cell death. Thiorphan may also inhibit NEP from enhancing bronchoconstriction and can be used in the study of respiratory diseases .

HY-18100A

PRE-084 hydrochloride 10+ Cited Publications	Sigma Receptor Akt NO Synthase	Cardiovascular Disease Neurological Disease
PRE-084 hydrochloride is a highly selective σ1 receptor (S1R) agonist, with an IC₅₀ of 44 nM. PRE-084 hydrochloride exhibits good neuroprotective effects, can improve motor function and motor neuron survival in mice. PRE-084 hydrochloride also can ameliorate myocardial ischemia-reperfusion injury in rats by activating the Akt-eNOS pathway .

HY-B1065

Aceglutamide α-N-Acetyl-L-glutamine; N2-Acetylglutamine	Keap1-Nrf2 Akt ASK1 Apoptosis	Neurological Disease
Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) is a neuroprotectant that can penetrate the blood-brain barrier. Aceglutamide can enhance the antioxidant systems of glutathione (GSH), thioredoxin (Trx) and Nrf2. Aceglutamide also inhibits ASK1 and TRAF1, activates the Akt/Bcl-2 anti-apoptotic pathway, enhances the activity of antioxidant enzymes and reduces oxidative damage. Aceglutamide can improve neurological deficits after cerebral ischemia, reduce infarct volume, and inhibit neuronal apoptosis, especially substantia nigra dopaminergic neurons. Aceglutamide can reduce cerebral ischemia/reperfusion injury, improve motor dysfunction, and is used in ischemic stroke-related research .

HY-100834

5,7-Dichlorokynurenic acid 1 Publications Verification 5,7-DCKA	iGluR	Neurological Disease
5,7-Dichlorokynurenic acid (5,7-DCKA) is a selective and competitive antagonist of the glycine site on NMDA receptor with a K_B of 65 nM. 5,7-Dichlorokynurenic acid reduces NMDA-induced neuron injury. 5,7-Dichlorokynurenic acid increases social interaction time, increases open arm exploration time, disinhibits suppressed conflict responding in rodent models. 5,7-Dichlorokynurenic acid exhibits anxiolytic-like activity in rodent models and supports exploration of glycine’s role in NMDA receptor-mediated synaptic transmission .

HY-120751

TROX-1	Calcium Channel	Neurological Disease
TROX-1 is a selective, orally active and brain-penetrant N-type calcium channel (Cav2.2) inhibitor with an IC₅₀ value of 0.11 μM. TROX-1 exerts state-dependent and use-dependent inhibition, preferentially targets open/inactivated channels, blocks depolarization-associated calcium influx, and fully blocks calcium influx in rat dorsal root ganglion neurons. TROX-1 reverses inflammatory-induced hyperalgesia, nerve injury-induced allodynia. TROX-1 can be used for the research of pain .

HY-N1353

Rhamnocitrin 2 Publications Verification	p38 MAPK	Cardiovascular Disease Inflammation/Immunology
Rhamnocitrin is an anti-inflammatory and antioxidant agent that targets STIM-1, NFATc3 and MAPK pathways and can scavenge DPPH (IC₅₀=28.38 mM). Rhamnocitrin selectively inhibits oxidative stress and inflammatory responses in vascular endothelial cells and neurons. Rhamnocitrin up-regulates miR-185 to inhibit STIM-1-mediated store-operated calcium entry (SOCE), thereby blocking NFATc3 nuclear translocation and downstream inflammatory factor expression, while inducing heme oxygenase HO-1 expression and regulating the ERK/p38 MAPK pathway, inhibiting antioxidant and pro-inflammatory cytokines (such as IL-6, IL-8) and adhesion molecules (such as ICAM-1, VCAM-1). Rhamnocitrin can be used in the study of endothelial-related inflammatory diseases (such as sepsis, acute lung injury, atherosclerosis) and neuroprotection (such as oxidative damage of PC12 cells) .

HY-P10638

TAT-CN21	CaMK	Cardiovascular Disease Neurological Disease
TAT-CN21 is a potent CaMKII inhibitor with an IC₅₀ of 77.2 nM. TAT-CN21 inhibits both calcium/calmodulin-dependent and autonomously activated CaMKII, blocks glutamate-induced translocation of CaMK IIα, and reverses the enhanced phosphorylation of CaMKII at Thr286 following excitotoxic injury. TAT-CN21 shows application potential in studies related to ischemic stroke by reducing neuronal excitotoxicity and exacerbating pre-existing long-term neuronal death prior to injury. TAT-CN21 improves definitive behaviors in rats with residual nerve injury without altering indicators such as mechanical/thermal hyperalgesia or spatial memory. TAT-CN21 can also be used in studies related to neuropathic pain .

HY-110285

ML382	Mas-related G-protein-coupled Receptor (MRGPR)	Neurological Disease
ML382 is a potent and selective MRGPRX1 (Mas-related G protein-coupled receptor X1, MrgX1) positive allosteric modulator, with an EC₅₀ of 190 nM .

HY-P11117

TAT-EE3	TRP Channel iGluR Calcium Channel	Neurological Disease
TAT-EE3 is a neuroprotective peptide which can uncouple TRPM2-NMDARs interaction. TAT-EE3 inhibits TRPM2-induced enhancement of NMDAR surface expression and current amplitude.TAT-EE3 protects neurons against ischemic injury in vitro and in vivo. TAT-EE3can be used for the study of ischemic stroke .

HY-N0307

Ciwujianoside B	Bcl-2 Family NF-κB DNA/RNA Synthesis Apoptosis	Cardiovascular Disease Neurological Disease
Ciwujianoside B is an orally active, blood-brain barrier penetrable radioprotective agent and memory enhancer. Ciwujianoside B reduces radiation-induced DNA damage, cell cycle arrest and apoptosis, downregulates NF-κB and the Bax/Bcl-2 ratio, and enhances the proliferative capacity of bone marrow cells. Ciwujianoside B enhances object recognition memory in normal mice and induces dendritic extension in primary cultured cortical neurons. Ciwujianoside B can be used in studies related to hematopoietic system radiation injury and memory enhancement .

HY-108615

CP-316819 GPi 819	Phosphorylase	Cardiovascular Disease Neurological Disease Metabolic Disease
CP-316819 (GPi 819) is a blood-brain barrier permeable glycogen phosphorylase inhibitor. CP-316819 inhibits hepatic glycogenolysis, safely reduces blood glucose in type 2 diabetes, and rarely induces hypoglycemia. CP-316819 increases brain glycogen reserves, protects neurons, alleviates hypoglycemic brain injury, and inhibits excessive platelet activation, exerting both neuroprotective and vasculoprotective effects. CP-316819 can be used in research related to hypoglycemia, thrombosis, autoimmune inflammatory diseases, and type 2 diabetes .

HY-108448

N-Oleoyldopamine OLDA	TRP Channel Lipoxygenase	Cardiovascular Disease Neurological Disease Metabolic Disease
N-Oleoyldopamine (OLDA) is an orally active TRPV1 activator and 5-LOX inhibitor with blood-brain barrier permeability. N-Oleoyldopamine excites histaminergic neurons in the tuberomammillary nucleus via a dopamine receptor mechanism, a process independent of TRPV1 and cannabinoid receptors. On one hand, N-Oleoyldopamine promotes the release of insulin and glucose-dependent insulinotropic polypeptide through a GPR119-dependent pathway to improve glucose tolerance; on the other hand, N-Oleoyldopamine improves left ventricular function and reduces myocardial infarction size by triggering the release of substance P and calcitonin gene-related peptide. N-Oleoyldopamine is used in studies related to glycemic abnormalities and myocardial ischemia-reperfusion injury .

HY-17471AR

Metformin hydrochloride (Standard) 1,1-Dimethylbiguanide hydrochloride (Standard)	Reference Standards AMPK Autophagy Mitophagy Apoptosis mTOR	Cardiovascular Disease Metabolic Disease Cancer
Metformin hydrochloride (Standard) is the analytical standard of Metformin hydrochloride (HY-17471A). This product is intended for research and analytical applications. Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .

HY-14604

Xaliproden hydrochloride 1 Publications Verification SR57746A; SR57746 hydrochloride	5-HT Receptor Dopamine Receptor Trk Receptor PKC ERK Akt JNK	Neurological Disease Metabolic Disease
Xaliproden (SR57746) hydrochloride (SR57746A) is an orally active, highly selective 5-HT1A receptor agonist. Xaliproden hydrochloride activates pertussis toxin-sensitive G protein-coupled signaling cascades, as well as the PKC, ERK1/ERK2, Akt and p21 Ras/MEK-1 pathways. Xaliproden hydrochloride also downregulates the JNK/p66/c-Jun signaling pathway, induces phosphorylation of the shc adaptor protein, regulates extracellular dopamine and 5-HT levels, and induces [ ³⁵S]GTPγS labeling in rat brain structures rich in 5-HT1A receptors. Xaliproden hydrochloride exerts neurotrophic, neuroprotective, renoprotective, anti-inflammatory, anti-apoptotic, anti-fibrotic and analgesic effects. Xaliproden hydrochloride also enhances NGF-induced neurite outgrowth, promotes motor neuron survival, attenuates renal tubular injury and inhibits chemotherapy-induced mechanical allodynia, without activating or altering NGF-induced TrkA receptor activation. Xaliproden hydrochloride can be used in the research of motor neuron disease, diabetic nephropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, acute tonic nociceptive pain, inflammatory pain, depression and anxiety .

HY-19667A

BMS-561392 formate 2 Publications Verification DPC 333 formate	TNF Receptor NF-κB Apoptosis p38 MAPK	Neurological Disease Inflammation/Immunology
BMS-561392 formate (DPC 333 formate) is a selective ADAM17(TACE) inhibitor. BMS-561392 formate inhibits TNF-α secretion by regulating signaling pathways such as p44 MAPK and NF-κB. BMS-561392 formate also affects the survival of central nervous system-related cells including oligodendrocytes and microglia. BMS-561392 formate promotes microglial apoptosis, enlarges the injury area and exacerbates astrogliosis in a mouse spinal cord injury model. BMS-561392 formate can be used in research related to spinal cord injury and inflammatory diseases .

HY-D1631

Calcium Green-5N AM	Fluorescent Dye Calcium Channel	Neurological Disease
Calcium Green-5N AM is a Ca ²⁺-sensitive fluorescent probe (K_d = 14 μM). Calcium Green-5N AM shows enhanced fluorescence intensity upon binding to Ca ²⁺, and it can monitor free Ca ²⁺ in neurons .

HY-111573

KCL-286 C286	RAR/RXR	Others Neurological Disease Inflammation/Immunology
KCL-286 (C286) is an orally active and brain-penetrant retinoic acid receptor (RAR) β2 agonist (EC₅₀ = 1.9 nM). KCL-286 targets RARβ2 with good selectivity over RAR α (EC₅₀ = 26 nM) and RAR γ (EC₅₀ = 11 nM). KCL-286 activates RARβ2 in the injured neurons. KCL-286 induces axonal regeneration of both spinal and sensory nerves through the inhibitory environment of the CNS, modulates neuroinflammation and extracellular matrix molecules. KCL-286 can modulate the expression of CSPGs by neuronal secretion of decorin which promotes myelination and aids axonal growth. KCL-286 can be studied in research for area such as spinal cord injury and traumatic nerve injury .

HY-13918

Etimizol Ethimizole; Ethymisol; Ethymisole	Potassium Channel	Neurological Disease
Etimizol(Ethymisole; Antiffine; Ethylnorantifein) was shown to relieve amnesia effectively in the origin of which there is the hypoxic component (hypobaric hypoxia, actinomycin D, mechanical injury of the brain). Etimizol can decrease the K- ⁺ permeability of neurons' membrane during action potential.

HY-120327

KY-226 2 Publications Verification	Phosphatase	Neurological Disease Metabolic Disease
KY-226 is a potent, selective, orally active and allosteric protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC₅₀ of 0.25 μM, and without PPARγ agonist activity. KY-226 exerts anti-diabetic and anti-obesity effects by enhancing insulin and leptin signaling, respectively. KY-226 also protects neurons from cerebral ischemic injury .

HY-P6437A

Drp1 peptide inhibitor P110 TFA	Dynamin	Cardiovascular Disease Neurological Disease
Drp1 peptide inhibitor P110 (Compound P110) TFA is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 TFA can inhibit the activation of Drp1, prevent MPTP (HY-15608)-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 TFA can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .

HY-15800A

CZC-25146	TNK1 LRRK2	Neurological Disease Inflammation/Immunology
CZC-25146 is a potent and orally active LRRK2 inhibitor with IC₅₀ values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 can be used to research Parkinson's disease and liver diseases .

HY-105343

BW-180C 1 Publications Verification [D-Ala2, D-Leu5]-Enkephalin; DADLE	Opioid Receptor	Neurological Disease
BW-180C ([D-Ala2, D-Leu5]-Enkephalin; DADLE) is an δ opioid receptor (DOR) agonist, which belongs to the enkephalin family. Neuroprotective agent. BW-180C reversibly inhibits cellular transcription in neurons without causing cell injury .

HY-P6437

Drp1 peptide inhibitor P110	Dynamin	Cardiovascular Disease Neurological Disease
Drp1 peptide inhibitor P110 (Compound P110) is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 can inhibit the activation of Drp1, prevent MPTP-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .

HY-B0627S

Metformin-d6 1,1-Dimethylbiguanide-d₆	Isotope-Labeled Compounds AMPK Autophagy Mitophagy Apoptosis mTOR	Cardiovascular Disease Cancer
Metformin-d₆ (1,1-Dimethylbiguanide-d₆) is a deuterated labeled Metformin (HY-B0627). Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .

HY-19667

BMS-561392 DPC 333	TNF Receptor NF-κB Apoptosis p38 MAPK	Neurological Disease Inflammation/Immunology
BMS-561392 (BMS-561392) is a selective ADAM17(TACE) inhibitor. BMS-561392 inhibits TNF-α secretion by regulating signaling pathways such as p44 MAPK and NF-κB. BMS-561392 also affects the survival of central nervous system-related cells including oligodendrocytes and microglia. BMS-561392 promotes microglial apoptosis, enlarges the injury area and exacerbates astrogliosis in a mouse spinal cord injury model. BMS-561392 can be used in research related to spinal cord injury and inflammatory diseases .

HY-P5142

ω-Hexatoxin-Hv1a ω-ACTX-Hv1; ω-Atracotoxin-HV1	Insecticide Calcium Channel Apoptosis Necroptosis	Cardiovascular Disease Neurological Disease Inflammation/Immunology
ω-Hexatoxin-Hv1a (ω-ACTX-Hv1; ω-Atracotoxin-HV1) is an orally active insecticidal neurotoxin containing an inhibitor cystine knot motif and a selective calcium channel inhibitor. ω-Hexatoxin-Hv1a blocks L-type voltage-dependent Ca ²⁺ channels and reduces intracellular calcium ion concentration, thereby decreasing apoptosis, necroptosis and oxidative stress, and promoting cell recovery and energy level elevation. ω-Hexatoxin-Hv1a causes larval paralysis and death by impairing neurotransmission in the central nervous system of insects. It shows high injectable toxicity against insects of multiple orders, but exhibits weak oral toxicity. ω-Hexatoxin-Hv1a is widely applicable to studies related to ischemia-reperfusion injury, atopic dermatitis, and ischemic injury of cardiomyocytes and neurons .

HY-N12277

Celosin K	Apoptosis	Neurological Disease
Celosin K (compound 8) can be isolated from the seeds of Semen Celosiae. Celosin K is a potent inhibitor of **neuron injury elicited by t-BHP. Celosin K inhibits oxidative stress and apoptosis, and acts of autophagy** .

HY-N14827

Xanthofulvin SM-216289	Drug Derivative	Neurological Disease
Xanthofulvin (SM-216289) is an inhibitor of semaphorin 3A. Xanthofulvin blocks its binding to receptors, inhibits growth cone collapse, and accelerates olfactory nerve regeneration in rats in vivo. Xanthofulvin can be used in studies related to traumatic neuronal injury .

HY-18100

PRE-084	Sigma Receptor Akt NO Synthase	Cardiovascular Disease Neurological Disease
PRE-084 is a highly selective σ1 receptor (S1R) agonist, with an IC₅₀ of 44 nM. PRE-084 exhibits good neuroprotective effects, can improve motor function and motor neuron survival in mice. PRE-084 also can ameliorate myocardial ischemia-reperfusion injury in rats by activating the Akt-eNOS pathway .

HY-175548

Nrf2 activator-21	Keap1-Nrf2 Apoptosis Caspase	Neurological Disease
Nrf2 activator-21 is a Nrf2 activator with dual antioxidant and neuroprotective properties. Nrf2 activator-21 binds to Keap1 Kelch domain and disrupts Keap1-Nrf2 interactions and activate antioxidant defense mechanisms. Nrf2 activator-21 reduces apoptosis and decreases caspase-3 activity in the hippocampal neurons. Nrf2 activator-21 targets cerebral ischemia/reperfusion injury (CIRI) via Nrf2 pathway activation. Nrf2 activator-21 improves neurological function, alleviates anxiety-like behavior, enhances memory in rats with 2-vessel occlusion (2VO)-induced CIRI. Nrf2 activator-21 can be used for the study of cerebral ischemia/reperfusion injury .

HY-126049

(S)-Oxiracetam (S)-(-)-Oxiracetam; (S)-ISF2522	Apoptosis	Neurological Disease
(S)-oxiracetam (S-ORC) is an inhibitor targeting apoptosis. S-ORC reduces brain infarct size and lessens neurological dysfunction in middle cerebral artery occlusion/reperfusion (MCAO/R) models. S-ORC prevents neuronal apoptosis via activating PI3K/Akt/GSK3β signaling pathway via α7 nAChR after ischemic stroke. S-ORC can prevent neuronal death after ischemic stroke .

HY-P991380

TXB4	Transferrin Receptor	Neurological Disease
TXB4 is a brain-permeable human monoclonal antibody (mAb) targeting CD71. TXB4 prevents 6-OHDA-induced death of TH-positive neurons in the SNc in a 6-OHDA mouse model of Parkinson's disease (PD). TXB4 can be used in neurodegenerative diseases, acute brain and spinal cord injury, and depression research .

HY-176248

Dimephosphon	Histamine Receptor Serotonin Transporter	Neurological Disease Inflammation/Immunology
Dimephosphon is an anti-inflammatory agent with antihistamine and antiserotonin activities. Dimephosphon helps maintain the conduction function of the spinal cord and reduces the excitability of spinal motor neurons in the area surrounding the lesion. Dimephosphon directly activates lymphatic vessel movement and improves lymphatic circulation. Dimephosphon can be used for the study of inflammatory edema, acute spinal cord injury and lymphatic circulation disorders .

HY-P11124

MGF24	Apoptosis PKC Keap1-Nrf2 Heme Oxygenase (HO) Drug Derivative	Neurological Disease
MGF24 is a modified protease-resistant MGF derivative. MGF24 protects dopaminergic neurons from 6-Hydroxydopamine (6-OHDA) (HY-113028)-induced apoptosis by inducing Heme oxygenase-1 (HO-1). MGF24 activates PKC-ε, which in turn activates Nrf2, up-regulating HO-1. MGF24 has neuroprotective activity and reduces myocardial infarct size in sheep models of myocardial ischemia. MGF24 can be used for neurological diseases like stroke, nerve injury and amyotrophic lateral sclerosis research .

HY-147681

SUN13837	FGFR	Neurological Disease
SUN13837 is an orally active, blood-brain barrier permeable FGFR modulator and neuroprotective agent. SUN13837 mimics the activity of basic fibroblast growth factor, stimulates intracellular tyrosine phosphorylation of FGFR and signal transduction in neuronal cells, induces neurite outgrowth, and inhibits glutamate-induced neuronal death. SUN13837 can be used in research related to acute cervical spinal cord injury and severe spinal cord injury .

HY-B0627A

Metformin (glycinate) 1,1-Dimethylbiguanide (glycinate)	AMPK Autophagy Mitophagy Apoptosis mTOR	Cardiovascular Disease Metabolic Disease Cancer
Metformin (1,1-Dimethylbiguanide) glycinate inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin glycinate exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin glycinate also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin glycinate regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .

HY-15800

CZC-25146 hydrochloride	TNK1 LRRK2	Neurological Disease Inflammation/Immunology
CZC-25146 hydrochloride is a potent LRRK2 inhibitor with IC₅₀ values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 hydrochloride inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 hydrochloride prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 hydrochloride exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 hydrochloride can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 hydrochloride can be used to research Parkinson's disease and liver diseases .

HY-B0627S1

Metformin-13C2 hydrochloride 1,1-Dimethylbiguanide-13C2 hydrochloride	Isotope-Labeled Compounds AMPK Autophagy Mitophagy Apoptosis mTOR	Cardiovascular Disease Metabolic Disease Cancer
Metformin- ¹³C₂ (1,1-Dimethylbiguanide- ¹³C₂) hydrochloride is the ¹³C-labeled Metformin hydrochloride (HY-17471A). Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .

HY-N8693

Withanoside IV	COX Amyloid-β Sirtuin Reactive Oxygen Species (ROS) Apoptosis SARS-CoV	Infection Neurological Disease
Withanoside IV is an orally active, blood-brain barrier-permeable withanolide derivative. Withanoside IV specifically binds to the Sudlow I site of HSA, induces secondary structural changes in HSA, and forms stable HSA complexes. Withanoside IV inhibits the enzymatic activity of COX-2. Withanoside IV induces axonal regeneration, peripheral nervous system myelination and increased axonal density in spinal cord tissue, reduces reactive gliosis-related changes, and improves hindlimb motor function. Withanoside IV binds to amyloid-β 1-42 to inhibit its aggregation, induces neurite outgrowth and synapse reconstruction, repairs damaged axons and dendrites, enhances mitochondrial biogenesis, exerts neuroprotective effects via the BDNF and SIRT1 signaling pathways, reduces ROS production and neuronal apoptosis, and ameliorates memory deficits. Withanoside IV inhibits the activity of the SARS-CoV-2 main protease. Withanoside IV can be used in research related to spinal cord injury, Alzheimer's disease, and coronavirus disease 2019 (COVID-19) .

HY-100834R

5,7-Dichlorokynurenic acid (Standard) 5,7-DCKA (Standard)	Reference Standards iGluR	Neurological Disease
5,7-Dichlorokynurenic acid (Standard) is the analytical standard of 5,7-Dichlorokynurenic acid (HY-100834). This product is intended for research and analytical applications. 5,7-Dichlorokynurenic acid (5,7-DCKA) is a selective and competitive antagonist of the glycine site on NMDA receptor with a K_B of 65 nM. 5,7-Dichlorokynurenic acid reduces NMDA-induced neuron injury. 5,7-Dichlorokynurenic acid increases social interaction time, increases open arm exploration time, disinhibits suppressed conflict responding in rodent models. 5,7-Dichlorokynurenic acid exhibits anxiolytic-like activity in rodent models and supports exploration of glycine’s role in NMDA receptor-mediated synaptic transmission .

HY-172583

Neuroprotective agent 9	Drug Derivative	Neurological Disease
Neuroprotective agent 9 (compound 7) is a neuroprotective agent. Neuroprotective agent 9 is promising for research of neuron injury such as cerebral apoplexy, cerebral injury, and neuropathic pain .

HY-100834A

5,7-Dichlorokynurenic acid sodium 5,7-DCKA sodium	iGluR	Neurological Disease
5,7-Dichlorokynurenic acid (5,7-DCKA) sodium is a selective and competitive antagonist of the glycine site on NMDA receptor with a K_B of 65 nM. 5,7-Dichlorokynurenic acid sodium reduces NMDA-induced neuron injury. 5,7-Dichlorokynurenic acid sodium increases social interaction time, increases open arm exploration time, disinhibits suppressed conflict responding in rodent models. 5,7-Dichlorokynurenic acid sodium exhibits anxiolytic-like activity in rodent models and supports exploration of glycine’s role in NMDA receptor-mediated synaptic transmission .

HY-P2862A

Neuron-specific enolase, Human	Enolase	Neurological Disease
Neuron-specific enolase, Human (EC 4.2.1.11), an enolase, is a biomarker in traumatic brain injury (TBI), stroke and anoxic encephalopathy after cardiac arrest and acute SCI as well .

HY-165492

Opc 14117	Reactive Oxygen Species (ROS) NF-κB Apoptosis	Neurological Disease Inflammation/Immunology
OPC-14117 is an orally active superoxide radical scavenger that can cross the blood-brain barrier. OPC-14117 inhibits the oxidative stress cascade reaction, significantly reducing the increase in tissue osmotic pressure and alleviating brain edema in the brain contusion model. OPC-14117 blocks the NF-κB-dependent apoptotic pathway in the striatum neuron apoptosis model induced by Quinolinic acid (HY-100807). OPC-14117 can reduce the necrotic volume, protect hippocampal CA3 neurons and restore cognitive function. OPC-14117 can be used to study secondary brain injury and improve neurological prognosis .

HY-18100AR

PRE-084 hydrochloride (Standard)	Reference Standards Sigma Receptor Akt NO Synthase	Cardiovascular Disease Neurological Disease
PRE-084 (hydrochloride) (Standard) is the analytical standard of PRE-084 (hydrochloride). This product is intended for research and analytical applications. PRE-084 hydrochloride is a highly selective σ1 receptor (S1R) agonist, with an IC50 of 44 nM. PRE-084 hydrochloride exhibits good neuroprotective effects, can improve motor function and motor neuron survival in mice. PRE-084 hydrochloride also can ameliorate myocardial ischemia-reperfusion injury in rats by activating the Akt-eNOS pathway .

HY-172455

TREK inhibitor-3	Potassium Channel	Neurological Disease
TREK inhibitor-3 (Cpd8l) is a selective and BBB-permeable TREK-1 inhibitor with an IC₅₀ of 0.81 μM. TREK inhibitor-3 has neuroprotective effects, which can significantly reduce the death of cortical neurons induced by oxygen-glucose deprivation/reoxygenation (OGD/R) and improve brain injury in mice models of middle cerebral artery occlusion/reperfusion (MCAO/R). TREK inhibitor-3 can be used in the research of ischemic stroke .

HY-162347

Nav1.7-IN-13	Sodium Channel	Neurological Disease
Nav1.7-IN-13 (compound 3g) is a sodium channel inhibitor that significantly inhibits Veratridine (HY-N6691)-induced neuronal activity. Nav1.7-IN-13 inhibits total Na+ current in DRG neurons in a concentration-dependent manner; slows down the activation of Navs. Nav1.7-IN-13 significantly alleviated mechanical pain behavior in a rat model of nerve injury (SNI) and had analgesic activity .

Cat. No.	Product Name

HY-L212

Neuropeptide Library

126 compounds

Neuropeptides are small proteins produced and released by neurons through the regulation of secretory pathways, expressed in neurons and have transmitter or co-transmitter functions, and are used as nerve substrates. Neuropeptides are by far the largest and most diverse signaling molecules in the brain and have been implicated in the development of diseases and drugs. Neuropeptides are involved in inflammatory and immune diseases and have an impact on epithelial, vascular, and connective tissue cells proliferation and tissue repair. Studies have shown that neuropeptides are particularly important when the nervous system is challenged, such as stress, injury, or substance abuse. Substance P is a neuropeptide that acts as a neurotransmitter and neuromodulator in the central nervous system and is currently in clinical research and has been shown to be involved in inflammatory processes and pain.

MCE can provide 126 neuropeptides that can be used for scientific research.

Cat. No.	Product Name	Target	Research Area

HY-P10638

TAT-CN21	CaMK	Cardiovascular Disease Neurological Disease
TAT-CN21 is a potent CaMKII inhibitor with an IC₅₀ of 77.2 nM. TAT-CN21 inhibits both calcium/calmodulin-dependent and autonomously activated CaMKII, blocks glutamate-induced translocation of CaMK IIα, and reverses the enhanced phosphorylation of CaMKII at Thr286 following excitotoxic injury. TAT-CN21 shows application potential in studies related to ischemic stroke by reducing neuronal excitotoxicity and exacerbating pre-existing long-term neuronal death prior to injury. TAT-CN21 improves definitive behaviors in rats with residual nerve injury without altering indicators such as mechanical/thermal hyperalgesia or spatial memory. TAT-CN21 can also be used in studies related to neuropathic pain .

HY-P11117

TAT-EE3	TRP Channel iGluR Calcium Channel	Neurological Disease
TAT-EE3 is a neuroprotective peptide which can uncouple TRPM2-NMDARs interaction. TAT-EE3 inhibits TRPM2-induced enhancement of NMDAR surface expression and current amplitude.TAT-EE3 protects neurons against ischemic injury in vitro and in vivo. TAT-EE3can be used for the study of ischemic stroke .

HY-P6437A

Drp1 peptide inhibitor P110 TFA	Dynamin	Cardiovascular Disease Neurological Disease
Drp1 peptide inhibitor P110 (Compound P110) TFA is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 TFA can inhibit the activation of Drp1, prevent MPTP (HY-15608)-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 TFA can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .

HY-105343

BW-180C 1 Publications Verification [D-Ala2, D-Leu5]-Enkephalin; DADLE	Opioid Receptor	Neurological Disease
BW-180C ([D-Ala2, D-Leu5]-Enkephalin; DADLE) is an δ opioid receptor (DOR) agonist, which belongs to the enkephalin family. Neuroprotective agent. BW-180C reversibly inhibits cellular transcription in neurons without causing cell injury .

HY-P6437

Drp1 peptide inhibitor P110	Dynamin	Cardiovascular Disease Neurological Disease
Drp1 peptide inhibitor P110 (Compound P110) is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 can inhibit the activation of Drp1, prevent MPTP-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .

HY-P5142

ω-Hexatoxin-Hv1a ω-ACTX-Hv1; ω-Atracotoxin-HV1	Insecticide Calcium Channel Apoptosis Necroptosis	Cardiovascular Disease Neurological Disease Inflammation/Immunology
ω-Hexatoxin-Hv1a (ω-ACTX-Hv1; ω-Atracotoxin-HV1) is an orally active insecticidal neurotoxin containing an inhibitor cystine knot motif and a selective calcium channel inhibitor. ω-Hexatoxin-Hv1a blocks L-type voltage-dependent Ca ²⁺ channels and reduces intracellular calcium ion concentration, thereby decreasing apoptosis, necroptosis and oxidative stress, and promoting cell recovery and energy level elevation. ω-Hexatoxin-Hv1a causes larval paralysis and death by impairing neurotransmission in the central nervous system of insects. It shows high injectable toxicity against insects of multiple orders, but exhibits weak oral toxicity. ω-Hexatoxin-Hv1a is widely applicable to studies related to ischemia-reperfusion injury, atopic dermatitis, and ischemic injury of cardiomyocytes and neurons .

HY-P11124

MGF24	Apoptosis PKC Keap1-Nrf2 Heme Oxygenase (HO) Drug Derivative	Neurological Disease
MGF24 is a modified protease-resistant MGF derivative. MGF24 protects dopaminergic neurons from 6-Hydroxydopamine (6-OHDA) (HY-113028)-induced apoptosis by inducing Heme oxygenase-1 (HO-1). MGF24 activates PKC-ε, which in turn activates Nrf2, up-regulating HO-1. MGF24 has neuroprotective activity and reduces myocardial infarct size in sheep models of myocardial ischemia. MGF24 can be used for neurological diseases like stroke, nerve injury and amyotrophic lateral sclerosis research .

HY-105343R

BW-180C (Standard) [D-Ala2, D-Leu5]-Enkephalin (Standard); DADLE (Standard)	Reference Standards Opioid Receptor	Neurological Disease
BW-180C (Standard) is the analytical standard of BW-180C (HY-105343). This product is intended for research and analytical applications. BW-180C ([D-Ala2, D-Leu5]-Enkephalin; DADLE) is an δ opioid receptor (DOR) agonist, which belongs to the enkephalin family. Neuroprotective agent. BW-180C reversibly inhibits cellular transcription in neurons without causing cell injury .

HY-P5142A

ω-Hexatoxin-Hv1a TFA ω-ACTX-Hv1 TFA; ω-Atracotoxin-HV1 TFA	Insecticide Apoptosis Calcium Channel Necroptosis	Cardiovascular Disease Neurological Disease Inflammation/Immunology
ω-Hexatoxin-Hv1a (ω-ACTX-Hv1; ω-Atracotoxin-HV1) TFA is an orally active insecticidal neurotoxin containing an inhibitor cystine knot motif and a selective calcium channel inhibitor. ω-Hexatoxin-Hv1a TFA blocks L-type voltage-dependent Ca ²⁺ channels and reduces intracellular calcium ion concentration, thereby decreasing apoptosis, necroptosis and oxidative stress, and promoting cell recovery and energy level elevation. ω-Hexatoxin-Hv1a TFA causes larval paralysis and death by impairing neurotransmission in the central nervous system of insects. It shows high injectable toxicity against insects of multiple orders, but exhibits weak oral toxicity. ω-Hexatoxin-Hv1a TFA is widely applicable to studies related to ischemia-reperfusion injury, atopic dermatitis, and ischemic injury of cardiomyocytes and neurons .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991380

TXB4	Transferrin Receptor	Neurological Disease
TXB4 is a brain-permeable human monoclonal antibody (mAb) targeting CD71. TXB4 prevents 6-OHDA-induced death of TH-positive neurons in the SNc in a 6-OHDA mouse model of Parkinson's disease (PD). TXB4 can be used in neurodegenerative diseases, acute brain and spinal cord injury, and depression research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-153169

6PPD-Q 5+ Cited Publications 6PPD-Quinone	Quinones Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Other Diseases Benzene Quinones Endogenous metabolite Disease Research Fields Source Classification	α-synuclein Environmental Pollutants
6PPD-Q (6PPD-Quinone) is an environmental pollutant that can be detected in human urine and is widely present in the environment. 6PPD-Q targets and binds to CNR2, CNR1, AA2AR, LCAT, and TRPA1, with CNR2 exhibiting the highest binding affinity, potentially acting as a CNR2 receptor agonist to activate cannabinoid receptors. 6PPD-Q induces intestinal inflammation and barrier damage by disrupting mitochondrial function, reducing neuronal glycolysis metabolites and TCA cycle intermediates, and exacerbating α-synuclein (α-syn) aggregation. 6PPD-Q is applicable in research on environmental toxicology, neurodegenerative diseases, and inflammation-related disorders .

HY-B1065

Aceglutamide α-N-Acetyl-L-glutamine; N2-Acetylglutamine	Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Keap1-Nrf2 Akt ASK1 Apoptosis
Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) is a neuroprotectant that can penetrate the blood-brain barrier. Aceglutamide can enhance the antioxidant systems of glutathione (GSH), thioredoxin (Trx) and Nrf2. Aceglutamide also inhibits ASK1 and TRAF1, activates the Akt/Bcl-2 anti-apoptotic pathway, enhances the activity of antioxidant enzymes and reduces oxidative damage. Aceglutamide can improve neurological deficits after cerebral ischemia, reduce infarct volume, and inhibit neuronal apoptosis, especially substantia nigra dopaminergic neurons. Aceglutamide can reduce cerebral ischemia/reperfusion injury, improve motor dysfunction, and is used in ischemic stroke-related research .

HY-N1353

Rhamnocitrin 2 Publications Verification	Cardiovascular Disease Flavonols Flavonoids other families Classification of Application Fields Phenols Polyphenols Plants Disease Research Fields Source Classification	p38 MAPK
Rhamnocitrin is an anti-inflammatory and antioxidant agent that targets STIM-1, NFATc3 and MAPK pathways and can scavenge DPPH (IC₅₀=28.38 mM). Rhamnocitrin selectively inhibits oxidative stress and inflammatory responses in vascular endothelial cells and neurons. Rhamnocitrin up-regulates miR-185 to inhibit STIM-1-mediated store-operated calcium entry (SOCE), thereby blocking NFATc3 nuclear translocation and downstream inflammatory factor expression, while inducing heme oxygenase HO-1 expression and regulating the ERK/p38 MAPK pathway, inhibiting antioxidant and pro-inflammatory cytokines (such as IL-6, IL-8) and adhesion molecules (such as ICAM-1, VCAM-1). Rhamnocitrin can be used in the study of endothelial-related inflammatory diseases (such as sepsis, acute lung injury, atherosclerosis) and neuroprotection (such as oxidative damage of PC12 cells) .

HY-N0307

Ciwujianoside B	Triterpenes Structural Classification Terpenoids Acanthopanax senticosus (Rupr. et Maxim.) Harms Plants Araliaceae Source Classification	Bcl-2 Family NF-κB DNA/RNA Synthesis Apoptosis
Ciwujianoside B is an orally active, blood-brain barrier penetrable radioprotective agent and memory enhancer. Ciwujianoside B reduces radiation-induced DNA damage, cell cycle arrest and apoptosis, downregulates NF-κB and the Bax/Bcl-2 ratio, and enhances the proliferative capacity of bone marrow cells. Ciwujianoside B enhances object recognition memory in normal mice and induces dendritic extension in primary cultured cortical neurons. Ciwujianoside B can be used in studies related to hematopoietic system radiation injury and memory enhancement .

HY-N12277

Celosin K	Triterpenes Structural Classification Celosia argentea Linn. Terpenoids Amaranthaceae Plants Pentacyclic Triterpenoids Source Classification	Apoptosis
Celosin K (compound 8) can be isolated from the seeds of Semen Celosiae. Celosin K is a potent inhibitor of **neuron injury elicited by t-BHP. Celosin K inhibits oxidative stress and apoptosis, and acts of autophagy** .

HY-N14827

Xanthofulvin SM-216289	Structural Classification Natural Products Microorganisms Source Classification	Drug Derivative
Xanthofulvin (SM-216289) is an inhibitor of semaphorin 3A. Xanthofulvin blocks its binding to receptors, inhibits growth cone collapse, and accelerates olfactory nerve regeneration in rats in vivo. Xanthofulvin can be used in studies related to traumatic neuronal injury .

HY-N8693

Withanoside IV	Structural Classification Withania somnifera Solanaceae Plants Steroids Source Classification	COX Amyloid-β Sirtuin Reactive Oxygen Species (ROS) Apoptosis SARS-CoV
Withanoside IV is an orally active, blood-brain barrier-permeable withanolide derivative. Withanoside IV specifically binds to the Sudlow I site of HSA, induces secondary structural changes in HSA, and forms stable HSA complexes. Withanoside IV inhibits the enzymatic activity of COX-2. Withanoside IV induces axonal regeneration, peripheral nervous system myelination and increased axonal density in spinal cord tissue, reduces reactive gliosis-related changes, and improves hindlimb motor function. Withanoside IV binds to amyloid-β 1-42 to inhibit its aggregation, induces neurite outgrowth and synapse reconstruction, repairs damaged axons and dendrites, enhances mitochondrial biogenesis, exerts neuroprotective effects via the BDNF and SIRT1 signaling pathways, reduces ROS production and neuronal apoptosis, and ameliorates memory deficits. Withanoside IV inhibits the activity of the SARS-CoV-2 main protease. Withanoside IV can be used in research related to spinal cord injury, Alzheimer's disease, and coronavirus disease 2019 (COVID-19) .

HY-N0307R

Ciwujianoside B (Standard)	Triterpenes Structural Classification Terpenoids Acanthopanax senticosus (Rupr. et Maxim.) Harms Plants Araliaceae Source Classification	Reference Standards Bcl-2 Family NF-κB DNA/RNA Synthesis Apoptosis
Ciwujianoside B (Standard) is the analytical standard of Ciwujianoside B. This product is intended for research and analytical applications. Ciwujianoside B is an orally active, blood-brain barrier penetrable radioprotective agent and memory enhancer. Ciwujianoside B reduces radiation-induced DNA damage, cell cycle arrest and apoptosis, downregulates NF-κB and the Bax/Bcl-2 ratio, and enhances the proliferative capacity of bone marrow cells. Ciwujianoside B enhances object recognition memory in normal mice and induces dendritic extension in primary cultured cortical neurons. Ciwujianoside B can be used in studies related to hematopoietic system radiation injury and memory enhancement.

HY-B1065R

Aceglutamide (Standard) α-N-Acetyl-L-glutamine (Standard); N2-Acetylglutamine (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Keap1-Nrf2 Akt ASK1 Apoptosis
Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) (Standard) is the analytical standard of Aceglutamide (HY-B1065). This product is intended for research and analytical applications. Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) is a neuroprotectant that can penetrate the blood-brain barrier. Aceglutamide can enhance the antioxidant systems of glutathione (GSH), thioredoxin (Trx) and Nrf2. Aceglutamide also inhibits ASK1 and TRAF1, activates the Akt/Bcl-2 anti-apoptotic pathway, enhances the activity of antioxidant enzymes and reduces oxidative damage. Aceglutamide can improve neurological deficits after cerebral ischemia, reduce infarct volume, and inhibit neuronal apoptosis, especially substantia nigra dopaminergic neurons. Aceglutamide can reduce cerebral ischemia/reperfusion injury, improve motor dysfunction, and is used in ischemic stroke-related research .

HY-N1353R

Rhamnocitrin (Standard)	Flavonols Structural Classification Flavonoids other families Phenols Polyphenols Plants Source Classification	Reference Standards Others p38 MAPK
Rhamnocitrin (Standard) is the analytical standard of Rhamnocitrin. This product is intended for research and analytical applications. Rhamnocitrin is an anti-inflammatory and antioxidant agent that targets STIM-1, NFATc3 and MAPK pathways and can scavenge DPPH (IC₅₀=28.38 mM). Rhamnocitrin selectively inhibits oxidative stress and inflammatory responses in vascular endothelial cells and neurons. Rhamnocitrin up-regulates miR-185 to inhibit STIM-1-mediated store-operated calcium entry (SOCE), thereby blocking NFATc3 nuclear translocation and downstream inflammatory factor expression, while inducing heme oxygenase HO-1 expression and regulating the ERK/p38 MAPK pathway, inhibiting antioxidant and pro-inflammatory cytokines (such as IL-6, IL-8) and adhesion molecules (such as ICAM-1, VCAM-1). Rhamnocitrin can be used in the study of endothelial-related inflammatory diseases (such as sepsis, acute lung injury, atherosclerosis) and neuroprotection (such as oxidative damage of PC12 cells) .

HY-N18471

5,7-Dihydroxytryptamine 5,7-DHP	Structural Classification Alkaloids Animals Indole Alkaloids Source Classification	Monoamine Oxidase 5-HT Receptor
5,7-Dihydroxytryptamine (5,7-DHP) is an autofluorescent (λ_ex≈365 nm), selective neurotoxin and a transport substrate for MAO-A and 5-HT. 5,7-Dihydroxytryptamine can specifically target and damage central and peripheral 5-HTergic neurons, while affecting 5-HT-related pathways and neurotransmitter balance. 5,7-Dihydroxytryptamine can be used to establish 5-HTergic neuron injury models for studies on neural development, neurodegenerative diseases, as well as mechanisms related to platelet function and retinal neurons .

HY-N18091

Tovophyllin A	Structural Classification Guttiferae Phenols Polyphenols Garcinia mangostana Linn. Plants Source Classification	Akt GSK-3 Keap1-Nrf2 NF-κB Apoptosis
Tovophyllin A is an orally active xanthonoid compound. Tovophyllin A exerts neuroprotective effects against Parkinson's disease by activating the Akt/GSK3β signaling pathway. Tovophyllin A protects mouse models of liver injury by activating Nrf2. Tovophyllin A exhibits protective anti-inflammatory activity in mouse models of acute lung injury. Tovophyllin A inhibits the activation of NF-κB and subsequent release of pro-inflammatory cytokines. Tovophyllin A reduces apoptotic cell death (Apoptosis). Tovophyllin A has antiplasmodial activity. Tovophyllin A shows cytotoxic activity against lung epithelial cancer cells and breast cancer cells. Tovophyllin A can be used in research related to Parkinson's disease, liver injury, acute lung injury, lung epithelial cancer, and breast cancer .

Cat. No.	Product Name	Chemical Structure

HY-B0627S

Metformin-d6

Metformin-d₆ (1,1-Dimethylbiguanide-d₆) is a deuterated labeled Metformin (HY-B0627). Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .

HY-B0627S1

Metformin-13C2 hydrochloride

Metformin- ¹³C₂ (1,1-Dimethylbiguanide- ¹³C₂) hydrochloride is the ¹³C-labeled Metformin hydrochloride (HY-17471A). Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks